While myCAFs, characterized by high expression of αSMA, TAGLN, CTGF and FAP, are involved in ECM remodeling, promoting cancer cell migration, invasion and therapy resistance [40, 75, 76], iCAFs, classified by expression of cytokine genes including LIF, IL1β, CSF3, CXCL10 and CCL2, exert immunosuppressive and tumor growth promoting functions in the TME [38, 40, 77]. The gene discussed is CCL2; the disease is neoplasm.